2 min read
Gossamer Bio to report Phase 3 lung disease drug results by end of February
Gossamer Bio's Phase 3 trial results for a lung disease drug, due by end of February, will test if a Phase 3 based on a Phase 2 subgroup analysis can succeed.
2 articles
Gossamer Bio's Phase 3 trial results for a lung disease drug, due by end of February, will test if a Phase 3 based on a Phase 2 subgroup analysis can succeed.
Grail's cancer blood test failed its main goal in a large NHS study, causing its stock to drop 47%.